RxDoctor Payments Data

Zachary Gitto, MD

Gastroenterology · Columbia, SCNPI 1295265445

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,152 of the $14,127 with a category attached, or 86.0%. Ipsen Biopharmaceuticals, Inc accounts for 89.7% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $12,648, more than ten times the $523 reported in 2021.

$14,127in general payments, 2019–2025

Across 29 payments — averaging $487.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$13K
  • AbbVie$332
  • ERBE USA Inc$244
  • Cook Medical LLC$192
  • Boston Scientific$174
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$152
  • plus $362 from 4 others

What the payments were for

  • Speaking & faculty fees$12,15286%
  • Travel & lodging$1741%
  • Food & beverage$1,70212%
  • Education$991%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,127 in reported general payments places this provider in the 85th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$51,264
Medicare patients
244
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin28$80,468
LinzessLinaclotide34$24,047
Ursodiol17$4,048
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl99$1,410
Pantoprazole Sodium67$821
Omeprazole38$491
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl26$440
Azathioprine14$366
Dicyclomine Hcl14$259
Mirtazapine12$167
Furosemide14$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$152$80,46828 claims
AbbVieLinzess$332$24,04734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →